2 recruiting, 2 unknown. 4 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 4 | Recruiting 2, Unknown 2 |
Follow Devintec Sagl: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Performance and Safety of Afluxin® in Patients With Gastroesophageal Reflux Disease Afluxin®, Placebo - Gastroesophageal Reflux Disease (GERD) | Not applicable | Recruiting | Devintec Sagl | 208 | 2025-07-02 | 2026-08-26 |
| Gelsectan® in the Treatment of Patients With Diarrhoea-predominant Irritable Bowel Syndrome Gelsectan®, Placebo - Irritable Bowel Syndrome (IBS), Irritable Bowel Syndrome of Diarrhea Type (IBS-D) | Not applicable | Recruiting | Devintec Sagl | 330 | 2024-10-22 | 2026-04-03 |
| Devintec OR-AT0222 Oral Gel for the Treatment of Canker Sores: A Double Blind, Randomized, Placebo Controlled Clinical Investigation OR-AT0222, Placebo - Recurrent Aphthous Ulcer | Not applicable | Unknown | Devintec Sagl | 46 | 2023-05-08 | 2023-07-25 |
| Efficacy and Safety, Tolerability of GA-AT0119 in IBS-C ARM A, ARM B - Irritable Bowel Syndrome With Constipation (IBS-C) | Not applicable | Unknown | Devintec Sagl | 60 | 2021-11-01 | 2022-02-15 |
Gastroesophageal Reflux (1) · Irritable Bowel Syndrome (1) · Stomatitis, Aphthous (1)
Italy (3) · Belgium (1) · Bulgaria (1) · France (1) · Spain (1)